GlassScriptPhysician profile
Sajeev B Menon
NPI 1811988819
$24,738.53
in general payments reported to CMS, 2019-2025
30 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,748 · 2021: $147 · 2022: $2,620 · 2023: $937 · 2024: $425 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425 · Honoraria: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.99 |
| Honoraria | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,090.12 | 2019-2021 | |
| Valeritas, INC. | $4,337.36 | 2019 | |
| Corcept Therapeutics | $1,983.47 | 2022-2024 | Korlym |
| Novo Nordisk INC | $681.81 | 2019-2024 | Rybelsus, Ozempic, Tresiba |
| Chiesi USA, INC. | $325.00 | 2025 | Myalept |
| Mannkind Corporation | $312.73 | 2019-2023 | Afrezza |
| Lilly USA, LLC | $293.98 | 2019-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $276.65 | 2022-2023 | Gvoke Hypopen |
| Amgen INC. | $241.30 | 2019-2020 | |
| Insulet Corporation | $168.03 | 2021-2023 | Omnipod |
| Radius Health, INC. | $148.14 | 2019-2023 | Tymlos |
| Medtronic Minimed, INC. | $125.09 | 2019-2020 | |
| Pfizer INC. | $124.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $111.90 | 2023 | Arexvy |
| Abbott Laboratories | $91.23 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $65.61 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $61.69 | 2023-2025 | |
| Medtronic, INC. | $51.22 | 2022-2023 | Minimed 780g |
| Dexcom, INC. | $43.21 | 2021-2025 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $35.03 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.17 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $31.09 | 2019 | |
| Cequr Corporation | $26.01 | 2023 | Cequr Simplicity |
| Becton, Dickinson and Company | $20.45 | 2022 | |
| Kyowa Kirin, INC. | $16.76 | 2023 | Crysvita |
| Eisai INC. | $15.33 | 2019 | |
| Antares Pharma, INC. | $12.69 | 2019 | |
| Endo Pharmaceuticals INC. | $12.15 | 2019 | |
| Clarus Therapeutics INC. | $2.60 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajeev Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.